Which cancers are linked to Agent Orange exposure?

Veterans often look for a plain list of "Agent Orange cancers." What they find is messier. It helps to know why.

An expert committee has reviewed this evidence for decades. It publishes updates as new studies appear. It does not simply call each cancer linked or not linked. Instead it sorts them by how strong the evidence is. The 2018 update uses three levels. There is sufficient evidence of an association. There is limited or suggestive evidence of an association. And there is inadequate or insufficient evidence to determine whether an association exists.

These levels describe how strong the published research is. They do not say how sure anyone can be about one veteran's illness.

For the chemicals of interest, the committee found sufficient evidence of an association with two things. One is soft tissue sarcomas. The other is B-cell lymphomas.

That lymphoma group is spelled out. It includes Hodgkin lymphoma and non-Hodgkin lymphomas. It also includes chronic lymphocytic leukemia and hairy-cell leukemia.

One more condition met the bar for this top category. It is monoclonal gammopathy of undetermined significance, usually shortened to MGUS. MGUS is not a cancer. It is an unusual protein found in the blood, and doctors watch it over time.

A longer list fell into limited or suggestive evidence of an association. It holds bladder cancer and laryngeal cancer. It holds cancers of the lung, bronchus, or trachea. It also holds prostate cancer, multiple myeloma, and AL amyloidosis.

This level means the research showed something real. But the findings were not steady or clean enough to reach the top level. Again, that is a statement about the evidence. It is not a measure of any one person's risk.

For every other specific type of cancer, the committee found the evidence inadequate or insufficient to determine whether an association exists. The report discussed many cancers one by one, and they landed here.

Inadequate evidence means the question is not settled. It does not mean the answer is no.

That is the sentence most worth taking with you, because it is so easy to misread. This research is hard to do. The exposure happened decades ago. The people exposed have since scattered. And each of these cancers is uncommon on its own. Categories have moved between updates as better studies arrived.

It is not a diagnosis, and it cannot be. Evidence reviews describe patterns across large groups. No test can trace one tumour back to one herbicide exposure from decades ago. Any source that claims otherwise is reaching too far.

It is also not a benefits ruling. Scientific review and administrative eligibility are separate. Different bodies run them, and the lists do not always match. Take questions about claims, coverage, and care to the agency that runs them. The answers there are concrete.

Get your service history on paper. Note where you served, when, and in what role. Decades later, this is the piece most often missing when someone needs it.

Make sure a current clinician knows about the exposure. A short note in your record travels with you. It gives context to whatever comes up later.

Keep up the ordinary checks. Whatever your exposure history, the screening for your age and sex still applies. It is still the most reliable tool you have.

And if a diagnosis has already come, this review can show you where it sits in the evidence. But the people treating you know your scans and your pathology. They are the ones who can talk about what happens next.

One feature of this review deserves emphasis. It has been repeated over decades. Cancers have moved between categories as new research arrived.

So a category is a snapshot of the evidence at one moment. It is not a permanent verdict. A veteran told years ago that their cancer was not associated with herbicide exposure may be going on an older edition. Checking the current version now and then is a reasonable thing to do.